It has been recognized for several decades that overt type 2 diabetes is delayed for a considerable period by the ability of pancreatic islets to compensate for the ambient insulin resistance, glucose toxicity and amyloid deposition [1], [2], [3], [4], [5], [6], [7], [8], [9], [10]. The gene discussed is INS; the disease is type 2 diabetes mellitus.